Nanostructured lipid carriers as a novel tool to deliver sclareol: physicochemical characterisation and evaluation in human cancer cell lines

• Autor(a) principal: Silva Marques Borges, Gabriel
• Data de Publicação: 2022
• Outros Autores: Dias Moura Prazeres, Pedro Henrique, Malachias de Souza, Ângelo, Yoshida, Maria Irene, Carneiro Vilela, José Mario, Teixeira Maciel e Silva, Aline, Silva Oliveira, Mariana, Assis Gomes, Dawidson, Spangler Andrade, Margareth, de Souza-Fagundes, Elaine Maria, Miranda Ferreira , Lucas Antônio
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Brazilian Journal of Pharmaceutical Sciences
• Texto Completo: https://www.revistas.usp.br/bjps/article/view/200989
• topic: Cancer. Sclareol. Solid lipid nanoparticles. Nanostructured lipid carriers. Small-angle X-ray scattering.

Sclareol (SC) is arousing great interest due to its cytostatic and cytotoxic activities in several cancer cell lines. However, its hydrophobicity is a limiting factor for its in vivo administration. One way to solve this problem is through nanoencapsulation. Therefore, solid lipid nanoparticles (SLN-SC) and nanostructured lipid carriers (NLC-SC) loaded with SC were produced and compared regarding their physicochemical properties. NLC-SC showed better SC encapsulation than SLN-SC and was chosen to be compared with free SC in human cancer cell lines (MDA-MB-231 and HCT-116). Free SC had slightly higher cytotoxicity than NLC-SC and produced subdiploid DNA content in both cell lines. On the other hand, NLC-SC led to subdiploid content in MDA-MB-231 cells and G2/M checkpoint arrest in HCT-116 cells. These findings suggest that SC encapsulation in NLC is a way to allow the in vivo administration of SC and might alter its biological properties.